If you’ve already registered, please click here to login to the webinar.
Single-cell genomics has progressed rapidly over the last decade since the development of single-cell DNA-sequencing (scDNA-seq) and single-cell RNA-sequencing (scRNA-seq) methods. The development of high-throughput systems such as nanowells, microdroplets, and microfluidic platforms has enabled thousands of cells to be sequenced in parallel—reducing costs to less than USD 1 per cell. Single-cell sequencing (SCS) methods offer many advantages over traditional “bulk” DNA-seq and RNA-seq approaches, which are limited to providing a mixed signal that represents many cell types in the microenvironment or an amalgamation of tumor clones with different genotypes.
SCS has impacted many areas of cancer research, improving our understanding of invasion in premalignant disease, intratumor heterogeneity, the tumor microenvironment, metastasis, and therapeutic resistance. Several areas of cancer medicine will be transformed by SCS, including early-detection diagnostics and risk stratification, drug target discovery, targeting the microenvironment, targeting tumor clones, and noninvasive monitoring. In the same way that next-generation sequencing (NGS) technologies have transformed modern oncology over the last decade, SCS methods will impact many areas of cancer research and will become a common tool in cancer centers.
This webinar discusses several cancer research studies, including a case study involving a rare form of melanoma in which resident memory T cells changed their responses after immune checkpoint blockade as well as another study that documents tissue-resident populations in breast cancer patients. Emerging technologies and future clinical applications that are bound to transform cancer research and medicine will also be mentioned.
During the webinar, viewers will:
If you’ve already registered, please click here to login to the webinar.